XML 29 R14.htm IDEA: XBRL DOCUMENT v3.23.1

Other Income	3 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
Other Income	OTHER INCOMEThe Company realized a $1.8 million gain in the first quarter of 2023 for previously paid prescription drug fees. In March 2023, the Company was granted a barrier-to-innovation waiver from the FDA for the fiscal year 2022 RediTrex prescription drug fees resulting in a refund of $1.8 million. This refund is expected to be paid in second quarter of 2023.

X

- References

No definition available.

+ Details

Name:	us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-URI https://asc.fasb.org/topic&trid=2122503

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 610
-URI https://asc.fasb.org/topic&trid=49130413

+ Details

Name:	us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration